Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTX NASDAQ:LIFE NASDAQ:OTLK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTXEntera Bio$1.65+1.2%$1.26$0.91▼$3.22$80.34M1.562.81 million shs471,716 shsLIFEEthos Technologies Inc. Class A Common Stock$18.90-3.5%$18.98$9.45▼$32.50$1.19BN/A521,853 shs303,132 shsOTLKOncobiologics$1.69-1.2%$0.71$0.16▼$3.39$239.48M0.9419.41 million shs7.83 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTXEntera Bio-0.06%+11.49%+22.22%+48.65%-13.16%LIFEEthos Technologies Inc. Class A Common Stock-3.47%+21.70%0.00%+1,889,999,900.00%+1,889,999,900.00%OTLKOncobiologics-1.17%-7.65%+131.51%+721.19%+5.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTXEntera Bio$1.65+1.2%$1.26$0.91▼$3.22$80.34M1.562.81 million shs471,716 shsLIFEEthos Technologies Inc. Class A Common Stock$18.90-3.5%$18.98$9.45▼$32.50$1.19BN/A521,853 shs303,132 shsOTLKOncobiologics$1.69-1.2%$0.71$0.16▼$3.39$239.48M0.9419.41 million shs7.83 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTXEntera Bio-0.06%+11.49%+22.22%+48.65%-13.16%LIFEEthos Technologies Inc. Class A Common Stock-3.47%+21.70%0.00%+1,889,999,900.00%+1,889,999,900.00%OTLKOncobiologics-1.17%-7.65%+131.51%+721.19%+5.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTXEntera Bio 2.00Hold$9.00445.45% UpsideLIFEEthos Technologies Inc. Class A Common Stock 2.33Hold$27.0042.86% UpsideOTLKOncobiologics 2.00Hold$6.50284.62% UpsideCurrent Analyst Ratings BreakdownLatest ENTX, OTLK, and LIFE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026OTLKOncobiologics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/24/2026ENTXEntera Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/11/2026OTLKOncobiologics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.00 ➝ $10.005/26/2026LIFEEthos Technologies Inc. Class A Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Sell (D)5/18/2026OTLKOncobiologics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral5/11/2026LIFEEthos Technologies Inc. Class A Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/8/2026LIFEEthos Technologies Inc. Class A Common Stock BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$20.00 ➝ $27.005/7/2026LIFEEthos Technologies Inc. Class A Common Stock Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$21.00 ➝ $27.004/27/2026ENTXEntera Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $9.004/22/2026LIFEEthos Technologies Inc. Class A Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold (C-)4/21/2026ENTXEntera Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTXEntera Bio$40K2,033.21N/AN/A$0.29 per share5.69LIFEEthos Technologies Inc. Class A Common Stock$485.82M2.45N/AN/AN/A∞OTLKOncobiologics$1.35M175.32N/AN/A($0.60) per share-2.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTXEntera Bio-$11.44M-$0.27N/AN/AN/AN/A-83.31%-70.83%8/14/2026 (Estimated)LIFEEthos Technologies Inc. Class A Common StockN/AN/AN/AN/AN/AN/AN/AN/AN/AOTLKOncobiologics-$62.42M-$1.17N/AN/AN/AN/AN/A-291.28%8/13/2026 (Estimated)Latest ENTX, OTLK, and LIFE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q2 2026OTLKOncobiologics-$0.12-$0.16-$0.04-$0.05$4.39 million$0.13 million5/8/2026Q1 2026ENTXEntera Bio-$0.08-$0.07+$0.01$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthENTXEntera BioN/AN/AN/AN/AN/ALIFEEthos Technologies Inc. Class A Common StockN/AN/AN/AN/AN/AOTLKOncobiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTXEntera BioN/A7.937.93LIFEEthos Technologies Inc. Class A Common StockN/AN/AN/AOTLKOncobiologicsN/A0.540.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTXEntera Bio14.11%LIFEEthos Technologies Inc. Class A Common Stock61.72%OTLKOncobiologics11.20%Insider OwnershipCompanyInsider OwnershipENTXEntera Bio10.57%LIFEEthos Technologies Inc. Class A Common Stock3.70%OTLKOncobiologics1.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTXEntera Bio2049.29 million44.08 millionOptionableLIFEEthos Technologies Inc. Class A Common Stock61462.99 millionN/AN/AOTLKOncobiologics20140.05 million137.53 millionOptionableENTX, OTLK, and LIFE HeadlinesRecent News About These CompaniesOncobiologics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of "Hold" from AnalystsJune 26, 2026 | americanbankingnews.comOncobiologics (NASDAQ:OTLK) Upgraded to Hold at Wall Street ZenJune 20, 2026 | americanbankingnews.comOTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for ReviewJune 17, 2026 | zacks.comOutlook Therapeutics Eye Drug Review Returns To FDA For Fourth TimeJune 17, 2026 | benzinga.comOutlook Therapeutics: Potential Catalysts Offering An Arbitrage OpportunityJune 6, 2026 | seekingalpha.comYezan Munther Haddadin Purchases 29,000 Shares of Oncobiologics (NASDAQ:OTLK) StockJune 4, 2026 | insidertrades.comOncobiologics (NASDAQ:OTLK) Director Buys $5,038,428.31 in StockJune 2, 2026 | insidertrades.comOutlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)June 1, 2026 | globenewswire.comOutlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 28, 2026 | globenewswire.comOutlook Shares Jump Following FDA Appeal Decision For LYTENAVAMay 26, 2026 | benzinga.comOutlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)May 26, 2026 | globenewswire.comOncobiologics, Inc. (OTLK) Reports Q2 Loss, Lags Revenue EstimatesMay 15, 2026 | zacks.comOutlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate UpdateMay 15, 2026 | globenewswire.comOutlook Therapeutics Announces Closing of $5.0 Million Registered Direct OfferingApril 23, 2026 | globenewswire.comOutlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesApril 22, 2026 | globenewswire.comOutlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVAâ„¢ (bevacizumab-vikg)April 21, 2026 | globenewswire.comOutlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDAApril 7, 2026 | globenewswire.comOutlook Therapeutics Announces Closing of $5.0 Million Public OfferingMarch 25, 2026 | globenewswire.comOutlook Therapeutics Announces Pricing of $5.0 Million Public OfferingMarch 24, 2026 | globenewswire.comOutlook Therapeutics Announces Proposed Public OfferingMarch 23, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENTX, OTLK, and LIFE Company DescriptionsEntera Bio NASDAQ:ENTX$1.65 +0.02 (+1.23%) Closing price 06/29/2026 04:00 PM EasternExtended Trading$1.60 -0.05 (-3.27%) As of 06/29/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Ethos Technologies Inc. Class A Common Stock NASDAQ:LIFE$18.90 -0.68 (-3.47%) As of 06/29/2026 04:00 PM EasternEthos Technologies Inc operates a technology-driven, direct-to-consumer platform for the distribution of life insurance products. Through its digital underwriting, data analytics, and proprietary technology, it enables consumers to explore, compare, and purchase life insurance policies online. The platform serves consumers, agents, and insurance carriers, and supports the application and policy issuance process through an online interface. The company works with insurance carriers to offer life insurance products in the United States through digital channels and independent agents. It generates revenue through commissions paid by carriers from policies activated and sold through its platform as well as from the provision of third-party administrator services for such policies.Oncobiologics NASDAQ:OTLK$1.69 -0.02 (-1.17%) Closing price 06/29/2026 04:00 PM EasternExtended Trading$1.70 +0.01 (+0.30%) As of 06/29/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Boom Has a Second Act—And It's Playing Out in Optics Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback? 5 Tech Stocks to Buy on the July Pullback Is OpenAI’s IPO Delay a Warning for AI Investors? onsemi: What the Market Gets Wrong, You Can Get Right 5 Places Investors Can Hide If the AI Trade Keeps Cracking MarketBeat Week in Review – 06/22 - 06/26 Qualcomm’s Investor Day Just Changed the Growth Story Forever Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
